The staphylococcus aureus peptidoglycan protects mice against the pathogen and eradicates experimentally induced infection

Rosanna Capparelli, Nunzia Nocerino, Chiara Medaglia, Giuseppe Blaiotta, Patrizia Bonelli, Domenico Iannelli

Research output: Contribution to journalArticlepeer-review

Abstract

Staphylococcus aureus, in spite of antibiotics, is still a major human pathogen causing a wide range of infections. The present study describes the new vaccine A170PG, a peptidoglycan-based vaccine. In a mouse model of infection, A170PG protects mice against a lethal dose of S. aureus. Protection lasts at least 40 weeks and correlates with increased survival and reduced colonization. Protection extends into drug-resistant (MRSA or VISA) and genetically diverse clinical strains. The vaccine is effective when administered - in a single dose and without adjuvant - by the intramuscular, intravenous or the aerosol routes and induces active as well as passive immunization. Of note, A170PG also displays therapeutic activity, eradicating staphylococci, even when infection is systemic. Sustained antibacterial activity and induction of a strong and rapid anti-inflammatory response are the mechanisms conferring therapeutic efficacy to A170PG.

Original languageEnglish
Article numbere28377
JournalPLoS One
Volume6
Issue number12
DOIs
Publication statusPublished - Dec 1 2011

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'The staphylococcus aureus peptidoglycan protects mice against the pathogen and eradicates experimentally induced infection'. Together they form a unique fingerprint.

Cite this